함께 비교하는 진짜 ADC · Antibody · CGT 데이터

AntibodystaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Docetaxel + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3

AntibodystaleImmunityBio, Inc.Phase 2

atezolizumab (Tecentriq, N-803 + Atezolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+4

AntibodystaleArrys TherapeuticsPhase 2

pembrolizumab (Keytruda, grapiprant and pembrolizumab)

Non-small Cell Lung Cancer Adenocarcinoma · Non-small Cell Lung Cancer Adenocarcinom

#Non-smallCellLungCancerAdenocarc#Antibody#Phase2#항체#면역항체+2

AntibodystaleBrightPath BiotherapeuticsPhase 2

pembrolizumab (Keytruda, GRN-1201 + Pembrolizumab)

Metastatic NSCLC · Metastatic NSCLC

#MetastaticNSCLC#Antibody#Phase2#항체#면역항체+2

AntibodystaleOncoMed Pharmaceuticals, Inc.Phase 1

Demcizumab (Demcizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase1#항체#면역항체+2

효능 ORR 0%임상시험 1상태 ACTIVE

AntibodystaleMerus B.V.Phase 3

Petosemtamab (Petosemtamab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#항체#면역항체+2

AntibodystaleAmMax Bio, Inc.Phase 2

pembrolizumab (Keytruda, AMG820 and pembrolizumab)

Pancreatic Cancer; Colorectal Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#항체#면역항체+3

효능 ORR 0.0%임상시험 1상태 ACTIVE

AntibodystaleTJ Biopharma Co., Ltd.Phase 3

Uliledlimab (Uliledlimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2

AntibodystaleBayerPhase 1

BAY1905254 (Bapotulimab, Bapotulimab (BAY1905254))

Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3

AntibodystaleChang Gung Memorial HospitalPreclinical

nivolumab (Opdivo, HNSCC patients have used Nivolumab)

HNSCC · HNSCC

#HNSCC#Antibody#Preclinical#항체#면역항체+2

AntibodystaleTJ Biopharma Co., Ltd.Phase 2

pembrolizumab (Keytruda, TJ107 +Pembrolizumab)

Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#Antibody#Phase2#항체#면역항체+3

AntibodystaleInflaRx GmbHPhase 2

Vilobelimab (Vilobelimab)

SCC - Squamous Cell Carcinoma of Skin · SCC - Squamous Cell Carcinoma of Skin

#SCC-SquamousCellCarcinomaofSkin#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleNational Cancer Centre, Singapo…Phase 2

Oregovomab (Oregovomab)

Epithelial Ovarian Cancer · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#Antibody#Phase2#항체#면역항체+2

효능 ORR 1%임상시험 1상태 ACTIVE

AntibodystaleSeoul National University Hospi…Phase 2

nivolumab (Opdivo, Gemcitabine+ nivolumab)

Recurrent or Metastatic Nasopharyngeal Carcinom · Recurrent or Metastatic Nasopharyngeal C

#RecurrentorMetastaticNasopharyng#Antibody#Phase2#항체#면역항체+2

효능 ORR 69.6%임상시험 1상태 ACTIVE

AntibodystaleAmsterdam UMC, location VUmcPhase 2

pembrolizumab (Keytruda, SABR + pembrolizumab)

NSCLC, Stage I · NSCLC, Stage I

#NSCLCStageI#Antibody#Phase2#항체#면역항체+4

효능 ORR 41%임상시험 1상태 ACTIVE

AntibodystaleBrown UniversityPhase 2

Ipilumumab (Ipilumumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2

AntibodystaleHospices Civils de LyonPhase 2

nivolumab (Opdivo, IP, Intraperitoneal, Intraperitoneal (IP) nivolumab infusion)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#항체#면역항체+2

CGTAAVBiologicstaleMeiraGTx, LLCPhase 2

AAV-GAD High Dose (AAV-GAD High Dose)

Parkinson's Disease · Parkinson's Disease

#ParkinsonsDisease#CGT#Phase2#세포유전치료#CAR-T+2

AntibodystaleAsan Medical CenterPhase 2

nivolumab (Opdivo, Regorafenib/Nivolumab)

Carcinoma, Hepatocellular; Hepatoma · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#Antibody#Phase2#항체#면역항체+5

효능 ORR 42%임상시험 1상태 ACTIVE

AntibodystaleCompugen LtdPhase 1

nivolumab (Opdivo, COM701 with Opdivo, COM701 with Opdivo (Nivolumab).)

Advanced Cancer; Ovarian Cancer · Advanced Cancer

#AdvancedCancer#Antibody#Phase1#항체#면역항체+3

효능 ORR 6%임상시험 1상태 ACTIVE

AntibodystaleBond Avillion 2 Development LPPhase 2

Sonelokimab (M1095, M1095 (Sonelokimab))

Psoriasis · Psoriasis

#Psoriasis#Antibody#Phase2#항체#면역항체+2

ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages)

AL Amyloidosis; Amyloidosis · AL Amyloidosis

#ALAmyloidosis#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

AntibodystalePresage BiosciencesPhase 1

nivolumab (Opdivo, Motolimod + Nivolumab)

HNSCC · HNSCC

#HNSCC#Antibody#Phase1#항체#면역항체+2

AntibodystaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 + nivolumab)

Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#항체#면역항체+3